- Home
- ARCC vs MRNA Comparison
ARCC vs MRNA Comparison
Compare ARCC & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ARCC | MRNA |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 11.5B |
| IPO Year | 2004 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ARCC | MRNA |
|---|---|---|
| Price | $18.86 | $51.66 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 12 |
| Target Price | $22.11 | ★ $33.00 |
| AVG Volume (30 Days) | 7.7M | ★ 9.4M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | ★ 9.96% | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ 1.86 | N/A |
| Revenue | N/A | ★ $19,263,000,000.00 |
| Revenue This Year | $6.65 | $6.38 |
| Revenue Next Year | $1.87 | $12.33 |
| P/E Ratio | $10.41 | ★ N/A |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $18.26 | $22.28 |
| 52 Week High | $23.63 | $55.20 |
Technical Indicators
Market Signals| Indicator | ARCC | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 38.91 | 71.28 |
| Support Level | $18.74 | $23.73 |
| Resistance Level | $20.28 | $55.20 |
| Average True Range (ATR) | 0.45 | 3.01 |
| MACD | -0.00 | 0.55 |
| Stochastic Oscillator | 14.83 | 86.41 |
Price Performance
Historical ComparisonAbout ARCC Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing in first lien senior secured loans (including unitranche loans, which are loans that combine both senior and subordinated debt, generally in a first lien position) and second lien senior secured loans. In addition to senior secured loans, the company also invests in subordinated loans and preferred equity, it also makes common equity investments.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.